We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Astellas’ Daily Organ Rejection Drug
FDA Approves Astellas’ Daily Organ Rejection Drug
July 26, 2013
The FDA July 19 approved Astellas Pharma’s Astagraf XL extended-release capsules for the prevention of organ rejection in patients receiving a kidney transplant.